中国肺癌杂志2025，Vol.28Issue(8)：621-628,8.DOI:10.3779/j.issn.1009-3419.2025.102.29
抗体偶联药物在晚期NSCLC中的临床进展和展望
Clinical Progress and Prospects of Antibody-drug Conjugates in Advanced NSCLC
摘要
Abstract
Advances in targeted therapy and immunotherapy have significantly improved clinical outcomes for pa-tients with advanced non-small cell lung cancer(NSCLC),reshaping treatment paradigms.However,most patients ultimately face drug resistance,with limited options for subsequent therapies and suboptimal treatment efficacy,presenting a prominent challenge in current clinical practice.Antibody-drug conjugates(ADCs),characterized by high efficacy and favorable safety profiles,have emerged as a promising therapeutic frontier in recent years.This systematic review provides a comprehensive overview of the latest advancements in ADCs-based therapies for lung cancer,alongside discussions of the prevailing challenges in this rapidly evolving domain.关键词
肺肿瘤/抗体偶联药物/生物标志物/毒性反应Key words
Lung neoplasms/Antibody-drug conjugates/Biomarker/Toxic reactions引用本文复制引用
钟雨玲,王婧怡,邬麟..抗体偶联药物在晚期NSCLC中的临床进展和展望[J].中国肺癌杂志,2025,28(8):621-628,8.基金项目
This paper was supported by the grants from Science and Technology Innovation Program of Hunan Province(No.2023SK4024),National Key Clinical Specialty Scientific Research Project(No.Z2023098),Hunan Provincial Health High-Level Talent Scientific Research Project(No.R2023125)and the Hunan Cancer Hospital Climb plan(No.ZX2020005-5)(All to Lin WU). 本文受湖南省科技创新计划(No.2023SK4024)、国家重点临床专科科研专项项目(No.Z2023098)、湖南省卫生健康高层次人才重大科研专项(No.R2023125)以及湖南省肿瘤医院"科研攀登计划"(No.ZX2020005-5)资助 （No.2023SK4024）
